Home > Insider Trading > Filing (0001209191-22-032322)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1457612	Genocea Biosciences Inc.	GNCA	Biological Products, (No Disgnostic Substances) (2836)	510596811

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1746342	Carmen Chang	2855 Sand Hill Road Menlo Park CA 94025		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-05-24	5,931,843	$0.07	4,445,093	No	4	S	Indirect	See Note 2
Common Stock	Disposition	2022-05-25	4,445,093	$0.08	0	No	4	S	Indirect	See Note 2

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Note 2
No	4	S	Indirect	See Note 2

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.060 to$0.0746, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth inthis footnote (1) to this Form 4.
The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.0675 to $0.0980, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.